Dr. Muhammad Asmal

Muhammad Asmal is a healthcare researcher and clinical scholar whose work centers on oncology therapeutics, with particular attention to emerging treatment strategies for gynecologic cancers. Affiliated with the pharmaceutical and clinical research community, contributions reflect engagement with translational medicine and evidence-based practice in oncology care.

Published research explores the use of lenvatinib in combination with pembrolizumab for advanced endometrial cancer following platinum-based chemotherapy. Through case-based analysis, this work highlights the clinical rationale, therapeutic potential, and safety considerations of integrating targeted therapy with immunotherapy in recurrent disease settings.

Current scholarship demonstrates a focus on innovative treatment pathways and real-world clinical application of novel regimens. As the available publication record is limited at present, the profile reflects emerging contributions to advancing therapeutic options and informing oncology practice through focused clinical reporting.